Related Experiment Video
Updated: Aug 26, 2025

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Bioavailability of nanomaterials: bridging the gap between nanostructures and their bioactivity
Mingjing Cao1, Chunying Chen1,2,3
1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, China.
Abstract:
Instead of the nanostructure and biological activity, this perspective highlights the metabolic processes from biotransformation to bioavailability, to bridge the gap between the cradle (structure design) and endpoint (efficacy and/or safety) of nanomedicines.
Related Concept Videos
Bioavailability: Overview
Factors Influencing Bioavailability: First-Pass Elimination
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .

